Drug discontinuation effects are part of the pharmacology of a drug

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 2, 2011, Pages 324-328

  Reidenberg, Marcus M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CLONIDINE; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLDOPA; NALTREXONE; NITRIC OXIDE; PLACEBO; PRASUGREL; PROPRANOLOL; PROSTAGLANDIN SYNTHASE; TAMSULOSIN; TERAZOSIN; THROMBOXANE B2; VERAPAMIL;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; ANGINA PECTORIS; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DEATH; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYMURIA; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; REBOUND; RECURRENT DISEASE; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; TREATMENT REFUSAL; TREATMENT WITHDRAWAL; UNSTABLE ANGINA PECTORIS; URINARY EXCRETION; WITHDRAWAL SYNDROME;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; AWARDS AND PRIZES; CARDIOVASCULAR AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHARMACEUTICAL PREPARATIONS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 80054782511     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.183285     Document Type: Article

References (48)

1. Alderman EL, Coltart DJ, Wettach GE, and Harrison DC (1974) Coronary artery syndromes after sudden propranolol withdrawal. Ann Int Med 81:625-627.
2. Bijsterveld NR, Moons AH, Meijers JC, Tijssen JG, Büller HR, Levi M, and Peters RJ (2002) Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 39:811-817. (Pubitemid 34185328)
3. Bijsterveld NR, Peters RJ, Murphy SA, Bernink PJ, Tijssen JG, and Cohen M (2003) Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) studies. J Am Coll Cardiol 42:2083-2089. (Pubitemid 37549889)
4. Black K, Shea C, Dursun S, and Kutcher S (2000) Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 25:255-261. (Pubitemid 30641002)
5. Blanco M, Nombela F, Castellanos M, Rodriguez-Yáñez M, García-Gil M, Leira R, Lizasoain I, Serena J, Vivancos J, Moro MA, et al. (2007) Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 69:904-910. (Pubitemid 47329591)
6. Chen H, Ren JY, Xing Y, Zhang WL, Liu X, Wu P, Wang RJ, and Luo Y (2009) Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase. Int J Cardiol 131:313-320.
7. Collet JP, Himbet F, and Steg PG (2000) Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 76:257-258.
8. Cubeddu LX and Seamon MJ (2006) Statin withdrawal: clinical implications and molecular mechanisms. Pharmacotherapy 26:1288-1296. (Pubitemid 44306889)
9. Debruyne FM, Witjes WP, Fitzpatrick J, Kirby R, Kirk D, and Prezioso D (1996) The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group. Eur Urol 30:369-376. (Pubitemid 26362881)
10. Duff HJ, Offord J, West J, and Catterall WA (1992) Class I and IV antiarrhythmic drugs and cytosolic calcium regulate mRNA encoding the sodium channel alpha subunit in rat cardiac muscle. Mol Pharmacol 42:570-574. (Pubitemid 23027617)
11. Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD, Granger CB, Erickson S, White K, and Steg PG (2004) Adherence to evidencebased therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 117:73-81. (Pubitemid 38953725)
12. Fatah K, Beving H, Albåge A, Ivert T, and Blombäck M (1996) Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient? Eur Heart J 17:1362-1366.
13. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ, and National Registry of Myocardial Infarction 4 Investigators (2005) Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 96:611-616. (Pubitemid 41207298)
14. Graves T, Hanlon JT, Schmader KE, Landsman PB, Samsa GP, Pieper CF, and Weinberger M (1997) Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med 157:2205-2210. (Pubitemid 27451146)
15. Heeschen C, Hamm CW, Laufs U, Böhm M, Snapinn S, and White HD (2003) Withdrawal of statins in patients with acute coronary syndromes. Circulation 107:e27.
16. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD, and Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators (2002) Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 105:1446-1452. (Pubitemid 34263276)
17. Hochberg Z, Pacak K, and Chrousos GP (2003) Endocrine withdrawal syndromes. Endocr Rev 24:523-538. (Pubitemid 37056242)
18. Houston MC (1981) Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. Am Heart J 102:415-430.
19. Jaffe JH (1980) Drug addiction and drug abuse, in The Pharmacologic Basis of Therapeutics (Gilman AG, Goodman LS, and Gilman A, eds) pp 550-551, Macmillan Publishing, New York.
20. Kizer JR and Kimmel SE (2001) Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards. Arch Intern Med 161: 1145-1158. (Pubitemid 32691511)
21. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Böhm M, and Nickenig G (2001) Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 88:1306-1307. (Pubitemid 33132103)
22. Lepor H (1998) Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group.Urology 51:901-906.
23. Lordkipanidzé M, Diodati JG, and Pharand C (2009) Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence. Pharmacol Ther 123:178-186.
24. Lowe FC (1994) (1994) Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 44:46-51.
25. McDonald JW and Ali M (1983) Recovery of cyclooxygenase activity after aspirin in populations of platelets separated on stractan density gradients. Prostaglandins Leukot Med 12:245-252. (Pubitemid 14242544)
26. Mousa SA, Forsythe MS, Bozarth JM, and Reilly TM (1993) Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor- 1. Cardiology 83:367-373. (Pubitemid 24024563)
27. Mushlin AI and Ghomrawi H (2010) Health care reform and the need for comparative- effectiveness research. N Engl J Med 362:e6.
28. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, and Jolly MK (1993) Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting- enzyme inhibitors. RADIANCE Study. New Engl J Med 329:1-7. (Pubitemid 23182871)
29. Petursson H and Lader MH (1981) Withdrawal from long-term benzodiazepine treatment. Br Med J 283:643-645. (Pubitemid 11052946)
30. Reidenberg MM (1971) Renal Function and Drug Action, W.B. Saunders Co., Philadelphia.
31. Reidenberg MM, ed (1974) Individualization of drug therapy. Med Clin North Am 58:905-1162.
32. Reidenberg MM, ed (1982) Clinical pharmacology of symptom control. Med Clin North Am 66:969-1187.
33. Reidenberg MM, Levy M, Warner H, Coutinho CB, Schwartz MA, Yu G, and Cheripko J (1978) Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther 23:371-374. (Pubitemid 8327797)
34. Reidenberg MM and Lowenthal DT (1968) Adverse nondrug reactions. N Engl J Med 279:678-679.
35. Risselada R, Straatman H, van Kooten F, Dippel DW, van der Lugt A, Niessen WJ, Firouzian A, Herings RM, and Sturkenboom MC (2009) Withdrawal of statins and risk of subarachnoid hemorrhage. Stroke 40:2887-2892.
36. Rosengarten B, Auch D, and Kaps M (2007) Effects of initiation and acute withdrawal of statins on the neurovascular coupling mechanism in healthy, normocholesterolemic humans. Stroke 38:3193-3197. (Pubitemid 350175736)
37. Scarborough J (1995) The opium poppy in Hellenistic and Roman medicine, in Drugsand Narcotics in History (Porter R and Teich M, eds) pp 17-18, Cambridge University Press. Cambridge, UK.
38. Schouten O, Hoeks SE, Welten GM, Davignon J, Kastelein JJ, Vidakovic R, Feringa HH, Dunkelgrun M, van Domburg RT, Bax JJ, et al. (2007) Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 100:316-320. (Pubitemid 47041993)
39. Sibon I and Orgogozo JM (2004)) Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 62:1187-1189. (Pubitemid 38456516)
40. Slome R (1973) Withdrawal of propranolol and myocardial infarction. Lancet 1:156.
41. Sposito AC, Carvalho LS, Cintra RM, Araújo AL, Ono AH, Andrade JM, Coelho OR, Quinaglia e Silva JC, and Brasilia Heart Study Group (2009) Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal. Atherosclerosis 207:191-194.
42. Subramanian BV, Bowles MJ, Khurmi NS, Davies AB, O'Hara MJ, and Raftery EB (1983) Calcium antagonist withdrawal syndrome: objective demonstration with frequency-modulated ambulatory ST-segment monitoring. Br Med J (Clin Res Ed) 286:520-521. (Pubitemid 13147632)
43. Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, Leung VK, Wong VW, and Chan FK (2010) Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 152:1-9.
44. Théroux P, Waters D, Lam J, Juneau M, and McCans J (1992) Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 327:141-145.
45. Thomas M and Mann J (1998) Increased thrombotic vascular events after change of statin. Lancet 352:1830-1831. (Pubitemid 28550081)
46. Vial JH, McLeod LJ, and Roberts MS (1991) Rebound elevation in urinary thromboxane B2 and 6-keto-PGF1α excretion after aspirin withdrawal. Adv Prostaglandin Thromboxane Leukot Res 21A:157-160.
47. Vrijens B, Vincze G, Kristanto P, Urquhart J, and Burnier M (2008) Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 336:1114-1117. (Pubitemid 351731741)
48. Yoburn BC, Luke MC, Pasternak GW, and Inturrisi CE (1988) Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE. Life Sci 43:1319-1324.